Rapidly increasing evidence has documented that endocrine disruptors (EDs) contribute substantially to disease and disability, particularly neurodevelopmental disorders, metabolic diseases, reproductive disorders, immune and thyroid dysfunctions, as well as hormone-related …
Does surgical management of ovarian endometriomas improve in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI)?
Endometriosis is a chronic condition affecting up to 11% of people presumed female at birth by the age of 44 years, characterised by the growth of tissue similar to the …
Endometriosis is a chronic gynecological condition defined by the ectopic presence of endometrial-like tissue outside the uterine cavity, often resulting in debilitating symptoms and significant impacts on quality of life. …
There is a lack of reliable data or evidence-based protocol for the management of deep infiltrating endometriosis (DIE) lesions in reproductive age women. This study examines ovarian reserves in women …
The female reproductive system represents a highly complex regulatory network governing critical physiological functions, encompassing reproductive capacity and endocrine regulation that maintains female physiological homeostasis. The in vitro simulation system …
Endometriosis can disrupt folliculogenesis due to elevated levels of pro-inflammatory cytokines, free radicals, and the apoptotic response in granulosa cells (GCs). It can cause fertility issues in women. To date, …
Endometriosis (EMs) is a common gynaecological condition with high recurrence rates after fertility-preserving laparoscopic surgery, and optimal postoperative medical treatment remains unclear.
Endometriosis, a chronic inflammatory condition often characterized by chronic pelvic pain, significantly impacts women's quality of life. While psychological distress, including depression and anxiety, is prevalent in women with endometriosis, …
Endometriosis-related dysmenorrhea and pelvic pain impose significant economic and quality-of-life burdens. This study evaluated the cost-effectiveness of dienogest compared to gonadotropin-releasing hormone agonists (GnRH-a) for managing dysmenorrhea and pelvic pain …